Cerdulatinib-impurities | Pharmaffiliates

Cerdulatinib

Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)). Reference standards of Cerdulatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Cerdulatinib - API Standards 
    [catalogue_number] => PA 03 3830000
    [category_ids] => ,75,76,78,70,82,
    [chemical_name] => 
    [weight] => 445.54
    [form] => C20H27N7O3S
    [cas] => 1198300-79-6
    [pslug] => 1198300-79-6-cerdulatinib-api-pa033830000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 03 3830000

Cerdulatinib - API Standards


  • Catalogue No.:PA 03 3830000

  • CAS :

    1198300-79-6

  • Molecular Formula : C20H27N7O3S

  • Molecular Weight : 445.54